Search clinical trials for: mycophenolate mofetil [CellCept]

Total 933 results

Teva Branded Pharmaceutical Products R&D, Inc.
Parexel

Terminated

Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients

Stable Renal Transplant Recipients
Samsung Medical Center

Unknown

Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept (NODAT)

Diabetes

Korea, Republic of
National Institute of Diabetes and Digestive and...

Terminated

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . (ICCRN RCT2)

Interstitial Cystitis | Painful Bladder Syndrome

United States, Canada
Nanjing University School of Medicine

Completed

Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN

Nephritis | Henoch-Schoenlein Purpura

China
Nanjing University School of Medicine

Completed

MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis

Vasculitis | Anti-Neutrophil Cytoplasmic Antibody

China
University of Minnesota
Wyeth is now a wholly owned subsidiary of Pfizer; Roche Pharma AG; Genzyme, a...

Completed

Calcineurin Inhibitor Sparing After Kidney Transplantation (CNI-Sparing)

CNI Side Effects

United States
Rabin Medical Center

Unknown

CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients (MMF)

Renal Transplant

Israel
University of Pennsylvania
Novartis Pharmaceuticals

Terminated

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Transplants and Implants

United States
University of Washington
Genentech, Inc.

Completed

Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

Diabetic Nephropathies | Kidney Failure, Chronic | Glomerulonephritis, IGA | Hypertension, Renal
Oklahoma Medical Research Foundation
NYU Langone Health

Completed

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

Arthritis | Systemic Lupus Erythematosus

United States
University of California, San Francisco

Withdrawn

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk (STIFLE-RISK)

Infection | Transplant;Failure,Kidney

United States
Roxane Laboratories

Completed

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Prophylaxis of Organ Rejection

United States
Roxane Laboratories

Completed

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions

Prophylaxis of Organ Rejection

United States
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions

Healthy

India
University of Washington
Hoffmann-La Roche

Completed

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

Diabetic Nephropathies | Kidney Failure, Chronic | Glomerulonephritis, IGA | Hypertension, Renal

United States
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Pemphigus Vulgaris

United States, Spain, Israel, Australia, France, Argentina, Canada, Turkey, Germany, Brazil, Italy, Ukraine
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Hoffmann-La Roche

Completed

A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients

Lung Transplantation

Germany
Hoffmann-La Roche

Completed

CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants

Kidney Transplantation

Canada
Hoffmann-La Roche

Completed

A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation

Kidney Transplantation

France
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions

FED

India
Boston University
Aspreva Pharmaceuticals

Completed

Mycophenolate Mofetil in Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

United States
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Fasting

India
Hoffmann-La Roche

Terminated

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.

Kidney Transplantation

Germany
Roxane Laboratories

Completed

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions

Prophylaxis of Organ Rejection

United States
Roxane Laboratories

Completed

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions

Prophylaxis of Organ Rejection

United States
Hoffmann-La Roche

Terminated

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Heart Transplantation

France, Germany, United States, Australia, Spain, Austria
Chulalongkorn University

Completed

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Lupus Nephritis

Thailand
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting Conditions

Healthy

India
Northwell Health
Hoffmann-La Roche; New York Presbyterian Hospital; University of Medicine and...

Completed

Pilot Study of Mycophenolate Mofetil in Congenital Uropathies

Congenital Urological Abnormalities

United States
University of Pittsburgh

Completed

Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention

Graft Versus Host Disease | Allogeneic Blood and Marrow Transplantation (BMT)

United States
University of Texas Southwestern Medical Center
Roche Pharma AG; Biogen

Completed

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Mayo Clinic
Roche Pharma AG

Completed

CellCept in p-ANCA Vasculitis

Microscopic Polyangiitis | MPO-ANCA Vasculitis

United States
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

Healthy

United States
University of Texas Southwestern Medical Center
Aspreva Pharmaceuticals

Completed

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Multiple Sclerosis

United States
Nova Scotia Health Authority

Completed

Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation

Acute Rejection of Renal Transplant

Canada
Martin, Paul
National Cancer Institute (NCI)

Terminated

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Cancer

United States, Canada
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil Tablets Under Fasting Conditions

Healthy

Canada
Guy's and St Thomas' NHS Foundation Trust
Institute of Child Health, University College London, London, UK.

Completed

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) (MISSILE)

Systemic Lupus Erythematosus | Atherosclerosis

United Kingdom
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil Tablets Under Fed Conditions

Healthy

Canada
University of Miami
Novartis Pharmaceuticals

Completed

Myfortic vs. Cellcept in Kidney Transplant Recipients

End Stage Renal Disease

United States
Nanjing University School of Medicine

Completed

Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy

IGA Nephropathy

China
Hoffmann-La Roche
Aspreva Pharmaceuticals

Completed

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Myasthenia Gravis Generalised

France, Ukraine, Germany, United States, Italy, United Kingdom, Former Serbia and Montenegro
University of Giessen
Novartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg University

Completed

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Polyomavirus Infections

Germany
University of Rochester
Batten Disease Support and Research Assocation (BDSRA)

Completed

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JUMP)

Juvenile Neuronal Ceroid Lipofuscinosis

United States
Novartis Pharmaceuticals

Terminated

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Renal Transplantation

United States
Medical University of South Carolina
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Sirolimus Conversions in African-American Renal Transplant Recipients

Absence; Kidney

United States
Klemens Budde
Novartis Pharmaceuticals

Completed

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Immunosuppression | Transplantation | Drug Interaction

Germany
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States

Search clinical trials for: mycophenolate mofetil [CellCept]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations